Phase 2 trial of ixazomib, cyclophosphamide, and dexamethasone for previously untreated light chain amyloidosis

Eli Muchtar, Morie A. Gertz, Betsy R. LaPlant, Francis K. Buadi, Nelson Leung, Patrick O'Brien, P. Leif Bergsagel, Amie Fonder, Yi Lisa Hwa, Miriam Hobbs, Dania K. Helgeson, Erin E. Bradt, Wilson Gonsalves, Martha Q. Lacy, Prashant Kapoor, Mustaqueem Siddiqui, Jeremy T. Larsen, Rahma Warsame, Suzanne R. Hayman, Ronald S. GoDavid Dingli, Taxiarchis V. Kourelis, Angela Dispenzieri, S. Vincent Rajkumar, Shaji K. Kumar

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Phase 2 trial of ixazomib, cyclophosphamide, and dexamethasone for previously untreated light chain amyloidosis'. Together they form a unique fingerprint.

Medicine & Life Sciences